On Friday, January 31, 2025, pharmaceutical companies are scheduled to meet with officials from the Central Drugs Standard Control Organization (CDSCO) to discuss various regulatory matters. A key topic anticipated for discussion is the extension of the implementation timeline for the Revised Schedule M, which pertains to Good Manufacturing Practices (GMP) standards. Representatives from Micro, Small, and Medium Enterprises (MSMEs) in the pharmaceutical sector are expected to advocate for this extension.
The Revised Schedule M establishes enhanced quality standards and GMP for pharmaceutical manufacturers, aiming to improve overall manufacturing quality, safety, and regulatory compliance across the sector. In response to requests from manufacturing units, the Indian government has granted MSME pharmaceutical companies an additional year to comply with these standards, extending the deadline to December 31, 2025.
This meeting underscores the ongoing efforts to balance regulatory requirements with the operational realities of pharmaceutical manufacturers, particularly MSMEs, to ensure both compliance and the continued availability of quality medicin
es.
إرسال تعليق